BCM
DMK

BTR Capital Management’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

BTR Capital Management’s Portfolio DMK Stock Details DMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-143
Closed -$13K – 169
2019
Q2 		$13K Buy
+143
New +$17.4K ﹤0.01% 165

Other funds holding DMK

6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

BTR Capital Management's DMK Position: Q3 2019 in Review

BTR Capital Management sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q3 2019, closing a stake of 143 shares — an estimated $13K sold.

BTR Capital Management first reported a position in DMK in Q2 2019 and held it in 1 quarter. The position peaked at $13K in Q2 2019. 50 funds tracked by Wall St. Rank hold DMK as of Q3 2019.

  • BTR Capital Management reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q3 2019 after selling out during the quarter.
  • BTR Capital Management sold 143 DMK Pharmaceuticals Corporation Common Stock shares in Q3 2019, an estimated $13K.
  • BTR Capital Management first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q2 2019 and held it in 1 quarter.
  • BTR Capital Management's DMK Pharmaceuticals Corporation Common Stock position peaked at $13K in Q2 2019.
  • 50 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q3 2019.

Based on BTR Capital Management's 13F filing for Q3 2019, filed 21 Oct 2019.